ARVCF

Across TCGA pan-cancer cohorts, ARVCF Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARVCF data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ARVCF Mutation is associated with better overall survival. In most high-consensus cancer types, elevated ARVCF expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, LUAD, and THCA are the cancer types where ARVCF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	0.906	0.411	.032	16	view →
LUAD	OS	Median	All	0.384	0.702	.019	9	view →
THCA	DFS	Median	All	0.041	0.841	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	All	1.000	0.864	.023	4	view →
SCLC	OS	Median	All	0.219	0.650	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARVCF–BLCA (OS)

Open the BLCA breakdown →